P.104 Nintedanib in systemic sclerosis-associated interstitial lung disease: real-world multicenter cohort study on tolerability and discontinuation

Introduction Nintedanib slows progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD), but its tolerability is a potential concern. Material and Methods This multicenter study with patients followed up in specialist respiratory and rheumatology units evaluated tolerability and treatment-related interruption in SSc-ILD patients receiving nintedanib. Logistic regression identified factors associated with interruption, with multivariable adjustment for potential confounders. Fisher’s exact test was used when complete separation precluded logistic regression. Time to first treatment interruption was analysed by Cox regression. Wilcoxon signed-rank test was used to compare weight changes before and after treatment. Results Among 63 patients (mean age 56.5±13.8 years, 22% male), 76.2% received nintedanib 150 mg twice daily with the remainder 100 mg twice daily. Concomitant mycophenolate mofetil use and baseline gastrointestinal (GI) symptoms were reported in 85.7%. Baseline patient-reported GI symptoms after nintedanib included diarrhoea (14%), reflux (48%), and nausea/vomiting (32%). Over a median follow up of 22.2 months (95% CI 18.1-26.2), 51% of patients interrupted nintedanib due to diarrhoea (33%), nausea/vomiting (21%), reflux (2%), weight loss (9.5%), and abnormal liver function (5%) (multiple reasons allowed). Older age (p